Erica Doubleday, NP

Director of Advanced Practice Providers for the Cancer Service Line

Ochsner MD Anderson Cancer Center

Published Articles (1)

Monitoring for Interstitial Lung Disease With Trastuzumab Deruxtecan: A Practice-Changing Case

July 21, 2026

Antibody-drug conjugates (ADCs) combine the precision of targeted therapy with the cell-killing power of chemotherapy, and few have been more transformative in breast cancer than fam-trastuzumab deruxtecan (T-DXd)